IL303237A - Kinase inhibitors with an aminoheteroaryl skeleton - Google Patents

Kinase inhibitors with an aminoheteroaryl skeleton

Info

Publication number
IL303237A
IL303237A IL303237A IL30323723A IL303237A IL 303237 A IL303237 A IL 303237A IL 303237 A IL303237 A IL 303237A IL 30323723 A IL30323723 A IL 30323723A IL 303237 A IL303237 A IL 303237A
Authority
IL
Israel
Prior art keywords
optionally substituted
independently selected
alkyl
substituents independently
formula
Prior art date
Application number
IL303237A
Other languages
English (en)
Hebrew (he)
Inventor
Cheng Dai
Ding Qiang
He Zhixiang
Zhou Xiaobo
Zhou Yang
YIN Xiaohang
XIE Zeqiang
Original Assignee
Anrui Biomedical Tech Guangzhou Co Ltd
Allorion Therapeutics Inc
Cheng Dai
Ding Qiang
He Zhixiang
Zhou Xiaobo
Zhou Yang
YIN Xiaohang
XIE Zeqiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anrui Biomedical Tech Guangzhou Co Ltd, Allorion Therapeutics Inc, Cheng Dai, Ding Qiang, He Zhixiang, Zhou Xiaobo, Zhou Yang, YIN Xiaohang, XIE Zeqiang filed Critical Anrui Biomedical Tech Guangzhou Co Ltd
Publication of IL303237A publication Critical patent/IL303237A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of El Displays (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL303237A 2020-11-27 2021-11-26 Kinase inhibitors with an aminoheteroaryl skeleton IL303237A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020132454 2020-11-27
CN2021081236 2021-03-17
PCT/CN2021/133429 WO2022111621A1 (en) 2020-11-27 2021-11-26 Aminoheteroaryl kinase inhibitors

Publications (1)

Publication Number Publication Date
IL303237A true IL303237A (en) 2023-07-01

Family

ID=81753779

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303237A IL303237A (en) 2020-11-27 2021-11-26 Kinase inhibitors with an aminoheteroaryl skeleton

Country Status (10)

Country Link
US (2) US20240166635A1 (https=)
EP (2) EP4251613A4 (https=)
JP (2) JP2024506116A (https=)
KR (1) KR20230127228A (https=)
CN (2) CN116528869B (https=)
AU (3) AU2021385745C1 (https=)
CA (2) CA3202990A1 (https=)
IL (1) IL303237A (https=)
MX (1) MX2024006300A (https=)
WO (2) WO2022111621A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230127228A (ko) * 2020-11-27 2023-08-31 올오리온 테라퓨틱스 인크. 아미노헤테로아릴 키나아제 억제제
CA3207392A1 (en) * 2021-02-05 2022-08-11 Xiaoxia Yan Cdk inhibitor
EP4532473A1 (en) * 2022-05-27 2025-04-09 Allorion Therapeutics Inc. Aminoheteroaryl kinase inhibitors
EP4731620A1 (en) * 2023-06-25 2026-04-29 Allorion Therapeutics Inc Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
EP4725942A1 (en) * 2024-10-09 2026-04-15 Sibylla Biotech S.p.A. Compounds active on cyclin d1 pathway and their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
EP1343782B1 (en) * 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
KR100874791B1 (ko) * 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
GB0113041D0 (en) * 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
KR20040062557A (ko) * 2001-11-01 2004-07-07 얀센 파마슈티카 엔.브이. 글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003212282A1 (en) * 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
WO2006122003A2 (en) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
EP2125781A2 (en) * 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
RU2009140319A (ru) * 2007-04-02 2011-05-10 Палау Фарма С.А. (Es) Производные пирролпиримидина
NZ580671A (en) * 2007-04-16 2012-03-30 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
BRPI0810411B8 (pt) * 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
WO2009022171A1 (en) * 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
AR074209A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
CN103958482B (zh) * 2011-11-29 2017-06-09 健泰科生物技术公司 作为lrrk2调节剂的氨基嘧啶衍生物
NZ629830A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
CN110386901B (zh) * 2018-04-23 2022-11-25 上海医药工业研究院 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用
US12037323B2 (en) * 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
WO2020205560A1 (en) * 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
JP2023515629A (ja) * 2020-02-28 2023-04-13 フォチョン・バイオサイエンシーズ・リミテッド Ｃｄｋ２／４／６阻害剤としての化合物
WO2022096473A1 (en) * 2020-11-04 2022-05-12 Umicore A positive electrode active material for rechargeable batteries
KR20230127228A (ko) * 2020-11-27 2023-08-31 올오리온 테라퓨틱스 인크. 아미노헤테로아릴 키나아제 억제제
CA3207392A1 (en) * 2021-02-05 2022-08-11 Xiaoxia Yan Cdk inhibitor

Also Published As

Publication number Publication date
EP4436959A4 (en) 2026-02-11
CA3202990A1 (en) 2022-06-02
US20250002480A1 (en) 2025-01-02
WO2023093769A1 (en) 2023-06-01
KR20230127228A (ko) 2023-08-31
AU2025200001A1 (en) 2025-01-23
CN118475562A (zh) 2024-08-09
AU2021385745B2 (en) 2024-10-03
CA3238970A1 (en) 2023-06-01
JP2024541533A (ja) 2024-11-08
AU2022397678A1 (en) 2024-05-30
JP2024506116A (ja) 2024-02-09
EP4436959A1 (en) 2024-10-02
US20240166635A1 (en) 2024-05-23
EP4251613A1 (en) 2023-10-04
AU2021385745C1 (en) 2025-02-20
CN116528869B (zh) 2026-04-14
WO2022111621A1 (en) 2022-06-02
CN116528869A (zh) 2023-08-01
MX2024006300A (es) 2024-07-24
AU2021385745A9 (en) 2025-03-27
AU2021385745A1 (en) 2023-06-15
EP4251613A4 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
IL303237A (en) Kinase inhibitors with an aminoheteroaryl skeleton
TWI894229B (zh) 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物
KR102757890B1 (ko) 화합물, 조성물 및 방법
JP7626910B2 (ja) Ｒａｆキナーゼの阻害剤
AU2017286890B2 (en) Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections
US20250154148A1 (en) Kras inhibitors
ES2475206T3 (es) Derivados de oxima como inhibidores de HSP90
WO2019183589A1 (en) Modulators of eukaryotic initiation factor 2
WO2022135365A1 (en) Disubstituted cyclopentane kinase inhibitors
CA2957048A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US20250320185A1 (en) Aminoheteroaryl kinase inhibitors
US20240092761A1 (en) Quinazoline compounds and methods of use
EP4562016A2 (en) Cdk2 inhibitors and methods of using the same
TW202412784A (zh) 氮-喹唑啉化合物及使用方法
KR20220046593A (ko) 가교된 헤테로사이클일-치환된 피리미딘 화합물, 이의 제조 방법, 및 이의 약학 용도
WO2023017152A1 (en) Specific small molecule inhibitors that block kmt9 methyltransferase activity and function
HK40092567A (zh) 氨基杂芳基激酶抑制剂
WO2026006803A1 (en) 5-membered core compounds as modulators of werner syndrome recq dna helicase and uses thereof
EA052150B1 (ru) Новые спироциклогексановые производные, содержащие их фармацевтические композиции и их применение в качестве антиапоптотических ингибиторов
KR20250048158A (ko) 신규 스피로시클로헥산 유도체, 그를 함유하는 제약 조성물 및 항아폽토시스 억제제로서의 그의 용도
HK40041168B (en) Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof